J1R-MC-GZFD: A Parallel-Group Treatment, Phase 2, Double-Blind study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants with Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide who Failed to Achieve HbA1c Goal

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520328-27-00

Acronym

J1R-MC-GZFD

Enrollment

Registered

2025-07-04

Start date

2025-08-07

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 24]

Interventions

DRUGTirzepatide

DRUGNisotirotide

DRUGplacebo to match LY

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 24]	—

Countries

Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026